Vacoronium infusion guidline
Reading File
Finding Sources
Searching the Web
vecuronium infusion guideline ICU dose protocol
Reading File
Finding Sources
I now have comprehensive information. Here is the full vecuronium infusion guideline:
Vecuronium (Vecuronium Bromide) Infusion Guideline
Overview
Vecuronium is an intermediate-acting, non-depolarizing neuromuscular blocking agent (NMBA). It competitively antagonizes acetylcholine at nicotinic receptors at the neuromuscular junction. Onset is 1-2 minutes; duration of action is 30-40 minutes per dose.
Indications for Infusion
- Facilitation of mechanical ventilation in the ICU
- Maintenance of surgical muscle relaxation (intraoperative)
- Refractory status epilepticus requiring complete neuromuscular blockade
- ECMO support (when paralysis is needed)
- Pediatric ICU: mechanical ventilation support
Dosing
Adults
| Indication | Route | Dose |
|---|---|---|
| Intubation (RSI) | IV bolus | 0.08-0.12 mg/kg |
| Maintenance (intermittent) | IV bolus | 0.04 mg/kg initial, then 0.01 mg/kg every 15-20 min |
| Continuous infusion (intraoperative) | IV infusion | 1-2 mcg/kg/min |
| ICU infusion (mechanical ventilation) | IV infusion | 60-200 mcg/kg/hour (titrate in 10% increments) |
| Maximum dose | IV infusion | 0.2 mg/kg/hour |
After an intubating dose of 80-100 mcg/kg, the continuous infusion of 1 mcg/kg/min may be initiated approximately 20-40 minutes later, once early evidence of spontaneous recovery from the bolus dose is seen. - FDA Label / Pfizer
Pediatric (ICU)
| Age Group | Infusion Dose |
|---|---|
| Neonates | 0.11 ± 0.05 mcg/kg/hour |
| Infants / young children | 0.14 ± 0.05 mcg/kg/hour |
| Children (general range) | 0.05-0.08 mcg/kg/hour; bolus 0.05-0.1 mg/kg |
| Children 1-9 years | May need slightly higher dose and more frequent supplemental dosing |
Loading dose in pediatric patients: 0.1 mg/kg followed by maintenance infusion titrated to maintain 90% neuromuscular blockade by TOF (Train-of-Four) assessment. - Morgan and Mikhail's Clinical Anesthesiology, 7e, p. 402
Preparation / Reconstitution
- Add 5 mL sterile water for injection to 10 mg vecuronium powder → yields 2 mg/mL solution
- For IV bolus: Draw 2 mL (4 mg) + 2 mL NS 0.9% = 4 mL total at 1 mg/mL
- For continuous infusion (weight-based):
- Draw 2.5 mL/kg of reconstituted solution (= 5 mg/kg vecuronium)
- Add NS 0.9% or Glucose 5% to make 50 mL total
- Final concentration: 100 mcg/kg/mL
- Infusing at 1 mL/hour = 100 mcg/kg/hour
Compatible diluents: Normal saline (0.9% NaCl) or 5% Dextrose in water
Monitoring (MANDATORY)
All governing bodies - FDA, Pfizer label, and clinical guidelines - require peripheral nerve stimulation monitoring for ANY vecuronium infusion.
- Use a peripheral nerve stimulator (PNS) continuously to assess the degree of neuromuscular blockade
- Train-of-Four (TOF) is the standard monitoring method - aim for 1-2 twitches out of 4 for adequate ICU paralysis
- Do NOT give additional doses until a definite response to T1 or the first twitch is observed
- If no response to nerve stimulation: stop the infusion until a response returns
- Monitor neuromuscular transmission during both administration AND recovery phases
- Daily assessment: consider interruption (daily "drug holiday") to reassess need for ongoing paralysis
Metabolism & Excretion
- Primarily biliary excretion; 25% renal
- Metabolized in the liver to 3-hydroxy metabolite (active) - can accumulate with prolonged infusion
- Renal failure: duration moderately prolonged; no dose adjustment required for mild-moderate impairment, but dose reduction considered in anephric patients
- Hepatic failure: markedly prolonged duration; use with caution - Morgan and Mikhail's Clinical Anesthesiology, 7e, p. 401
Special Populations
| Population | Consideration |
|---|---|
| Women | ~30% more sensitive than men; greater blockade depth and longer duration |
| Postpartum | Further prolonged duration (altered hepatic blood flow) |
| Renal failure | Moderately prolonged; monitor carefully; consider dose reduction in anephric patients |
| Hepatic failure | Markedly prolonged; reduce dose, monitor closely |
| Neonates | Subsequent doses needed less frequently than adults |
| Elderly | Initial dose unchanged; but subsequent doses needed less frequently |
| Corticosteroid patients | Risk of prolonged post-ICU polyneuropathy (see Risks below) |
ICU-Specific Risks and Precautions
After long-term vecuronium infusion in ICU patients, prolonged neuromuscular blockade (up to several days) may persist after drug discontinuation, possibly from accumulation of its active 3-hydroxy metabolite.
Risk factors for prolonged blockade / ICU-acquired weakness:
- Female gender
- Renal failure
- Long-term or high-dose corticosteroid therapy
- Sepsis
In some patients, this can lead to the development of critical illness polyneuropathy/myopathy. The best clinical approach is to avoid unnecessary paralysis in critical care units. - Morgan and Mikhail's Clinical Anesthesiology, 7e, p. 401; Miller's Anesthesia, 10e
Reversal
- Sugammadex permits rapid reversal of deep vecuronium-induced neuromuscular blockade (preferred agent - encapsulates vecuronium directly)
- Neostigmine (anticholinesterase) can reverse moderate blockade, but ensure at least 1-2 twitches on TOF before administering
- Always give neostigmine with an anticholinergic (glycopyrrolate or atropine) to prevent bradycardia
Key Safety Points
- Vecuronium must only be administered under supervision of clinicians familiar with its actions and potential complications
- Facilities for intubation, artificial respiration, oxygen therapy, and reversal agents must be immediately available
- The clinician must be prepared to assist or control respiration at all times
- Vecuronium has no sedative or analgesic properties - always ensure adequate sedation and analgesia are provided concurrently (failure to do so causes patient awareness and suffering)
- In PICUs, many centers prefer cisatracurium over vecuronium for prolonged infusions due to organ-independent Hofmann elimination and lower risk of accumulation - Miller's Anesthesia, 10e
Note: The FDA label states that long-term IV infusion to support mechanical ventilation in the ICU "has not been studied sufficiently to support dosage recommendations." Therefore, all ICU infusion dosing should be individually titrated using peripheral nerve stimulation, not based on fixed protocols. The StatPearls vecuronium article provides a practical clinical summary aligned with these guidelines.
This is a shared conversation. Sign in to Orris to start your own chat.